Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.

Also called NCT01140581

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 402 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01140581
  • EudraCT 2009-016818-24
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Austria, Estonia, Finland, France, Germany, Israel, Italy, Mexico, Netherlands, Portugal, South Korea, Spain, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01140581. Randomized; no masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2011-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation
Acronym
ARTEMIS Load
Intervention (Drug)
DRONEDARONE
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01140581
Content hash
0a78965d9707770e938cc12907bbffad8991d104c7e2b7c7eda891a06e6e1643